These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34084399)

  • 1. Sulfatase-cleavable linkers for antibody-drug conjugates.
    Bargh JD; Walsh SJ; Isidro-Llobet A; Omarjee S; Carroll JS; Spring DR
    Chem Sci; 2020 Jan; 11(9):2375-2380. PubMed ID: 34084399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
    Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
    Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
    Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
    Chuprakov S; Ogunkoya AO; Barfield RM; Bauzon M; Hickle C; Kim YC; Yeo D; Zhang F; Rabuka D; Drake PM
    Bioconjug Chem; 2021 Apr; 32(4):746-754. PubMed ID: 33689309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
    Wang Y; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31288450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.
    Watanabe T; Arashida N; Fujii T; Shikida N; Ito K; Shimbo K; Seki T; Iwai Y; Hirama R; Hatada N; Nakayama A; Okuzumi T; Matsuda Y
    J Med Chem; 2024 Oct; 67(20):18124-18138. PubMed ID: 39410752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
    Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
    Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
    Harel ET; Drake PM; Barfield RM; Lui I; Farr-Jones S; Van't Veer L; Gartner ZJ; Green EM; Lourenço AL; Cheng Y; Hann BC; Rabuka D; Craik CS
    Antibodies (Basel); 2019 Nov; 8(4):. PubMed ID: 31694242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.